(Z)-1,2-Diphenylethene

(Z)-1,2-Diphenylethene

SCHEMBL819152

C(=C/c1ccccc1)\c1ccccc1.N.N

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.69
NFE2L2 Q16236 4/20 0.63
CYP19A1 P11511 2/20 0.63
MAOA P21397 2/20 0.63
MEN1 O00255 1/20 0.60
KMT2A Q03164 1/20 0.60
CHAT P28329 2/20 0.57
TRPA1 O75762 3/20 0.55
ALDH1A1 P00352 1/20 0.55
LMNA P02545 1/20 0.55
ALOX5 P09917 1/20 0.55
MAPK1 P28482 1/20 0.55
RELA Q04206 2/20 0.55
CYP11B1 P15538 1/20 0.55
CYP11B2 P19099 1/20 0.55
HDAC3 O15379 1/20 0.52
TNKS O95271 1/20 0.52
HDAC4 P56524 1/20 0.52
HDAC1 Q13547 1/20 0.52
HCAR2 Q8TDS4 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(Z)-1,2-Diphenylethene SCHEMBL1282295 1.00 MAOB (0.69) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL27480001 1.00 MAOB (0.69) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL1376696 1.00 MAOB (0.69) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL28186405 0.96 MAOB (0.65) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL347707 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL21847984 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL443 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL22712863 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL9134305 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1
(Z)-1,2-Diphenylethene SCHEMBL9488275 0.96 MAOB (0.73) MAOBNFE2L2CYP19A1MAOAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111138415-A Application of bifunctional chelating agent in uranium excretion promotion and radiation protection 中国人民解放军第四军医大学 2020-05-12 CN claimed
US-20100179323-A1 PROCESS FOR MAKING DIPHOSPINE-RUTHENIUM-DIAMINE COMPLEXES DR. REDDY'S LABORATORIES LIMITED (IN) 2010-07-15 US claimed
EP-1902061-B1 PROCESS FOR MAKING DIPHOSPHINE-RUTHENIUM-DIAMINE COMPLEXES REDDY S LAB EU LTD DR (GB) 2009-12-30 EP claimed
EP-1902061-A1 PROCESS FOR MAKING DIPHOSPHINE-RUTHENIUM-DIAMINE COMPLEXES Dow Gloval Technologies Inc. (US) 2008-03-26 EP claimed
WO-2007005550-A1 PROCESS FOR MAKING DIPHOSPHINE-RUTHENIUM-DIAMINE COMPLEXES DOW GLOBAL TECHNOLOGIES INC. (US) 2007-01-11 WO claimed
US-5763688-A HYDROGENATING A CARBONYL COMPOUND, RUTHENIUM-PHOSPHINE COMPLEX CATALYST, BASE, DIAMINE RESEARCH DEVELOPMENT CORPORATION OF JAPAN (JP) 1998-06-09 US claimed
US-4705757-A Method for fluorometric analysis of catechol amines TOYO SODA MANUFACTURING CO., LTD. (JP) 1987-11-10 US claimed
JP-56084881-A None JP disclosed
JP-6058930-A None JP disclosed
JP-56084880-A None JP disclosed
CN-116425753-A Pyrrolizine skeleton pyrimidine ring substituted derivative, preparation method thereof and flow battery 西安交通大学 2023-07-14 CN disclosed
CN-116368168-A Novel antimicrobial and antithrombotic medical device 列日大学 2023-06-30 CN disclosed
CN-114736240-A Phosphorus prodrugs of sGC stimulators 赛克里翁治疗有限公司 2022-07-12 CN disclosed
US-5210210-A CHIRAL AUXILIARIES AND THEIR USE IN THE SYNTHESIS OF CHIRAL MOLECULES THE BRITISH PETROLEUM COMPANY P.L.C. (GB) 1993-05-11 US disclosed
WO-1993003838-A1 CHIRAL CATALYSTS, CATALYTIC OXIDATION AND DISPROPORTIONATION REACTIONS, AND METHODS OF PRODUCING EPOXYCHROMANS AND TAXOL RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-03-04 WO disclosed
EP-0521099-A1 CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-01-07 EP disclosed
EP-0457469-A1 Chiral auxiliaries and their use in the synthesis of chiral molecules THE BRITISH PETROLEUM COMPANY P.L.C. (GB) 1991-11-21 EP disclosed
WO-1991014694-A1 CHIRAL CATALYSTS AND EPOXIDATION REACTIONS CATALYZED THEREBY RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1991-10-03 WO disclosed
JP-S5684880-A BATTERY WITH NONAQUEOUS ELECTROLYTE HITACHI MAXELL LTD 1981-07-10 JP disclosed
JP-S5684881-A BATTERY WITH NONAQUEOUS ELECTROLYTE HITACHI MAXELL LTD 1981-07-10 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179323-A1 PROCESS FOR MAKING DIPHOSPINE-RUTHENIUM-DIAMINE COMPLEXES DPY30, POP1, PPIP5K2 MAOB 4049/4885NFE2L2 2698/4885CYP19A1 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.